<div id="readability-page-1" class="page"><h3>Memorial Day Sale – Claim 70% Off TipRanks</h3><ul><li>Unlock trusted, data-backed investing tools with TipRanks Premium, from analyst ratings and forecasts to breaking news and portfolio analysis. </li><li>Discover high-conviction stock picks and new investing opportunities with the TipRanks Smart Investor Newsletter </li></ul>Immunic ( (IMUX) ) just unveiled an update. Immunic, Inc., a Nasdaq-listed late-stage biotechnology company focused on novel oral therapies for neurologic diseases, is centered on its lead multiple sclerosis candidate vidofludimus calcium, now in phase 3 trials in relapsing multiple sclerosis following positive phase 2 signals in several indications. The firm is positioning itself as a future commercial-stage neurology company, backed by a pipeline that includes IMU-856 and IMU-381 for neurodegenerative, chronic inflammatory and autoimmune-related diseases. On May 27, 2026, Immunic announced the appointment of veteran biopharmaceutical executive Erik Lundgren as chief executive officer, effective May 22, 2026, with his employment starting June 1, 2026, while former CEO Daniel Vitt, Ph.D., shifts to focus on scientific strategy and remains on the board. Lundgren, whose background includes leading Genentech’s commercial portfolio and helping launch the MS drug Ocrevus, is expected to steer Immunic through late-stage development, potential regulatory filings and commercialization of vidofludimus calcium, a transition underscored by an inducement grant of 1,000,000 stock options vesting over four years. The leadership change comes as Immunic advances its pivotal phase 3 ENSURE program in relapsing multiple sclerosis and prepares a planned phase 3 program in primary progressive multiple sclerosis, with a key phase 3 data readout in RMS anticipated by year-end 2026. Board chair Michael W. Bonney and Dr. Vitt emphasized that Lundgren’s MS and global commercial experience should bolster Immunic’s efforts to bring a differentiated, potentially next-generation MS therapy to market, signaling a critical phase for the company’s operational evolution and its stakeholders. The most recent analyst rating on (IMUX) stock is a Buy with a $27.00 price target. To see the full list of analyst forecasts on Immunic stock, see the IMUX Stock Forecast page. Spark’s Take on IMUX Stock According to Spark, TipRanks’ AI Analyst, IMUX is a Neutral. The score is held down primarily by weak financial performance (no revenue, large ongoing losses, and material cash burn), only partly offset by low debt. Technicals are comparatively supportive with the stock trading above key moving averages and positive MACD. Corporate events are a modest positive (Nasdaq compliance and experienced leadership additions), while valuation remains unattractive/unclear given negative earnings and no dividend. To see Spark’s full report on IMUX stock, click here. More about Immunic Immunic, Inc. is a late-stage biotechnology company developing novel oral therapies for neurologic diseases, with a primary focus on multiple sclerosis. Its lead candidate, vidofludimus calcium (IMU-838), is in phase 3 trials for relapsing multiple sclerosis, having previously shown activity in both relapsing and progressive forms of MS and other diseases, alongside earlier-stage programs targeting neurodegenerative and autoimmune conditions. The company aims to evolve into a commercial-stage neurology player by advancing vidofludimus calcium, which combines Nurr1-mediated neuroprotection with anti-inflammatory and antiviral effects via DHODH inhibition. Immunic’s broader pipeline, including IMU-856 and IMU-381, is designed to build a therapeutics platform for chronic inflammatory, neurodegenerative and autoimmune-related disorders, positioning the firm in a competitive but expanding neurologic treatment market. Average Trading Volume: 298,443 Technical Sentiment Signal: Buy Current Market Cap: $177.8M For a thorough assessment of IMUX stock, go to TipRanks’ Stock Analysis page.</div>

IMUX

Immunic, Inc. has appointed Erik Lundgren as CEO to lead its strategy for multiple sclerosis therapies, effective May 22, 2026. Lundgren, with experience from Genentech, will guide the company through late-stage development of its lead candidate, vidofludimus calcium, currently in phase 3 trials. The leadership change aims to enhance Immunic's position in the neurology market, supported by a pipeline targeting neurodegenerative and autoimmune diseases. Analyst ratings for IMUX stock remain mixed, with a current price target of $27.00.

Immunic Appoints New CEO to Lead MS Strategy